Procaryotic Micro-organism Patents (Class 435/71.2)
-
Publication number: 20110288025Abstract: Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell growth promotion effect, a collagen biosynthesis promotion effect, a wrinkle improvement effect, and an UV-induced cell damage inhibition effect. Accordingly, the folyl EFS can be used in a skin external application or cosmetic composition, a health supplement food composition, a feed composition, and a pharmaceutical composition.Type: ApplicationFiled: October 2, 2008Publication date: November 24, 2011Applicant: Damy Chemical Co., Ltd.Inventors: Boo Sun Cho, Kwang Nyeon Kim
-
Patent number: 8043833Abstract: The present invention provides enhanced methods of producing soluble, active fibroblast growth factor-20 (FGF-20), FGF-21, neurotrophin-3 (NT-3), growth hormone (GH), granulocyte colony stimulating factor (G-CSF), or glucocerebrosidase proteins in microorganisms that have an oxidizing environment.Type: GrantFiled: September 6, 2006Date of Patent: October 25, 2011Assignee: Novo Nordisk A/SInventors: Marc F. Schwartz, Bingyuan Wu, Aliakbar Mobasseri, Shawn A. DeFrees, Tarik Soliman, Karl F. Johnson
-
Patent number: 8017355Abstract: The present invention provides methods for producing recombinant peptides in a bacterial host utilizing a mannitol, arabitol, glucitol, or glycerol-inducible promoter, wherein the host bacterial cell that produces the peptide has been rendered incapable of degrading or metabolizing mannitol, arabitol, or glucitol, or derivatives or analogues thereof. The present invention provides bacterial cells that have been genetically altered to inhibit the metabolism or degradation of mannitol, glucitol, or arabitol, or derivatives or analogues thereof. The present invention utilizes mannitol, arabitol, glucitol, or glycerol to induce expression of a target polypeptide from an inducible promoter, allowing for the use of an inexpensive and stable carbon source inducer in the fermentation processes for the production of recombinant peptides.Type: GrantFiled: December 9, 2008Date of Patent: September 13, 2011Assignee: Pfenex, Inc.Inventors: J. Carrie Schneider, Bettina Rosner
-
Publication number: 20110217312Abstract: Immunogenic compositions and methods for eliciting an immune response against S. epidermidis and other related staphylococci are provided. The immunogenic compositions can include immunogenic conjugates of poly-?-glutamic acid (such as ?DLPGA) polypeptides of S. epidermidis, or related staphylococci that express a ?PGA polypeptide. The ?PGA conjugates elicit an effective immune response against S. epidermidis, or other staphylococci, in subjects to which the conjugates are administered. A method of treating an infection caused by a Staphylococcus organism that expresses cap genes is also disclosed. The method can include selecting a subject who is at risk of or has been diagnosed with the infection by the Staphylococcus organism which expresses ?PGA from the cap genes. Further, the expression of a ?PGA polypeptide by the organism can then be altered.Type: ApplicationFiled: February 25, 2011Publication date: September 8, 2011Inventors: Michael Otto, Stanislava Kocianova, Cuong Vuong, Jovanka Voyich, Yufeng Yao, Elizabeth Fischer, Frank De Leo
-
Patent number: 8003348Abstract: The present invention relates to a gene construct which is capable of achieving efficient production of an antimicrobial peptide in a microorganism, and a method for efficient mass production and separation of an antimicrobial peptide using the same. The gene construct of the present invention has a translationally coupled configuration of two independent and separate cistrons which encode an acidic peptide and a basic antimicrobial peptide, each having an opposite charge, under the control of a single promoter. The translationally coupled acidic peptide and basic antimicrobial peptide undergo charge-charge interaction simultaneously with expression thereof to neutralize the potential cytotoxicity of the antimicrobial peptide, resulting in prevention of antimicrobial peptide-mediated killing of host microorganisms. In addition, a conjugate of the acidic peptide and the antimicrobial peptide can be separated without chemical or enzymatic treatment.Type: GrantFiled: November 19, 2008Date of Patent: August 23, 2011Assignee: Korea Advanced Institute of Science and TechnologyInventors: Sun Chang Kim, Su A Jang, Bong Hyun Sung, Jung Min Kim, Ki Jung Lim, Ju Ri Shin, Ju Young Lee
-
Publication number: 20110200637Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: April 21, 2011Publication date: August 18, 2011Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20110136174Abstract: A method for producing cellulolytic enzyme, where clostridium microorganisms having cellulose utilizability are cultured, wherein after utilizable carbon source is consumed by the clostridium microorganisms, addition and consumption of the carbon source are repeated periodically to accumulate the cellulolytic enzyme in a culture medium.Type: ApplicationFiled: December 2, 2010Publication date: June 9, 2011Applicant: JAPAN INTERNATIONAL RESEARCH CENTER FOR AGRICULTURAL SCIENCESInventors: Akihiko KOSUGI, Yutaka MORI
-
Publication number: 20110117605Abstract: The invention relates to methods for manufacturing drug products comprising at least two distinct members of a polyclonal protein, for example a polyclonal antibody, where each distinct member is expressed by a separate population of cells. The methods involve at least an initial step in which the cell populations expressing the distinct members of the polyclonal protein are cultured separately. The individual cell populations, or proteins expressed by the individual cell populations, are combined at a later point of the upstream or downstream processing to result in a single drug product comprising the distinct members of the polyclonal protein.Type: ApplicationFiled: April 23, 2009Publication date: May 19, 2011Applicant: Symphogen A/SInventors: Anne Bondgaard Tolstrup, Lars Soegaard Nielsen, Dietmar Weilguny, Christian Müller, Finn C. Wiberg, Jonas Heilskov Graversen
-
Publication number: 20110100263Abstract: Disclosed is a Thermoanaerobacter sp. bacterial strain (BKH1) isolated from a hot spring, a purified protein (bioremediase) isolated from bacterial strain BKH1, as well as concrete compositions comprising BKH1 and/or the protein, and methods of using the protein and/or composition. Also disclosed are nucleic acids encoding the protein isolated from BKH1, as well as expression vectors, host cells, cell lines, and methods for generating and purifying the bioremediase protein.Type: ApplicationFiled: December 28, 2009Publication date: May 5, 2011Inventors: Brajadulal Chattopadhyay, Saroj Mandal
-
Publication number: 20110098207Abstract: The present invention provides recombinant bacterial cells for producing a detergent-additive protein. In some embodiments, the cells are of the genus Bacillus. In additional embodiments, the cells comprise a genome comprising an inactivated bglC gene, as well as a recombinant nucleic acid for production of at least one secreted detergent-additive protein. In some preferred embodiments, the secreted detergent-additive protein is a protease. The present invention also provides methods of using the bacterial cells to produce at least one detergent-additive protein, as well as cellulase-free compositions containing at least one detergent-additive protein.Type: ApplicationFiled: September 26, 2007Publication date: April 28, 2011Inventor: Marguerite A. Cervin
-
Publication number: 20110097444Abstract: An industrial method of reprocessing degumming residue from the initial purification of natural fats as well as a feed additive, which may be produced using the said method.Type: ApplicationFiled: April 22, 2009Publication date: April 28, 2011Inventors: Franciszek Baszczok, Waldemar Rymowicz
-
Patent number: 7923220Abstract: The present invention relates to a novel process for the production of interferon-beta in improved yields by fermentation.Type: GrantFiled: December 19, 2005Date of Patent: April 12, 2011Assignee: Cadila Healthcare LimitedInventors: Sanjeev Kumar Mendiratta, Vibhor Saraswat, Dharmedra Chudasama
-
Publication number: 20110077205Abstract: A compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical.Type: ApplicationFiled: November 20, 2008Publication date: March 31, 2011Applicant: LEIBNITZ-INSTITUT FUER MEERESWISSENSCHAFTENInventors: Johannes Imhoff, Zhiguo Yu, Gerhard Lang, Jutta Wiese, Holger Kalthoff, Stephanie Klose
-
Patent number: 7906280Abstract: The present invention describes methods for the production and use of single chain (single-stranded) fluorescence resonance energy transfer (“FRET”) DNA or RNA aptamers containing fluorophores (F) and quenchers (Q) at various loci within their structures, such that when its specific matching analyte is bound and the FRET-aptamers are excited by specific wavelengths of light, the fluorescence intensity of the system is modulated (increased or decreased) in proportion to the amount of analyte added. F and Q are covalently linked to nucleotide triphosphates (NTPs), which are incorporated by various nucleic acid polymerases such as Taq polymerase during the polymerase chain reaction (PCR) and then selected by affinity chromatographic, size-exclusion or molecular sieving, and fluorescence techniques. Further separation of related FRET-aptamers can be achieved by ion-pair reverse phase high performance liquid chromatography (HPLC) or other types of chromatography.Type: GrantFiled: May 12, 2006Date of Patent: March 15, 2011Inventors: John G. Bruno, Joseph Chanpong
-
Patent number: 7855059Abstract: A process for the production of a valuable compound, comprising the steps of a) fermentation of a filamentous bacterial or fungal strain (e.g. a Streptomyces strain or an Aspergillus strain) in a fermentation medium wherein a carbohydrate during fermentation is added in a cyclic pulse dosing/pause way, wherein the pulse dosing time is shorter than the pause time and b) recovery of the valuable compound from the fermentation broth.Type: GrantFiled: June 4, 2002Date of Patent: December 21, 2010Assignee: Novozymes A/SInventors: Kevin S. Wenger, Maria Antonieta Caicedo, Stuart Michael Stocks, Swapnil Bhargava, Mark R. Marten
-
Publication number: 20100317057Abstract: A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis.Type: ApplicationFiled: December 22, 2007Publication date: December 16, 2010Applicant: NOVO NORDISK A/SInventors: Jesper Faergeman Lau, Asser Sloth Andersen, Paw Bloch, Jesper Lau, Patrick William Garibay, Thomas Kruse, Inga Sig Nielsen Nørby, Claus Ulrich Jessen, Caspar Christensen, Jens Christian Norrild
-
Publication number: 20100304430Abstract: Methods to generate analogs of coenzyme A in vivo are disclosed. The methods to generate analogs of coenzyme A in a cell comprise reacting pantetheine or a derivative thereof with a reporter to form labeled pantetheine or a derivative thereof, contacting the cell with the labeled pantetheine or derivative thereof such that the labeled pantetheine or derivative thereof enters the cell, phosphorylating the labeled pantetheine or derivative thereof to form phosphopantetheine or a derivative thereof, adenylating the labeled phosphopantetheine or derivative thereof to form a labeled dephosphoCoenzyme A or derivative thereof, and phosphorylating the 3?-hydroxyl of the labeled dephosphoCoenzyme A or derivative thereof to form a labeled coenzyme A analog or derivative thereof.Type: ApplicationFiled: May 27, 2010Publication date: December 2, 2010Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael D. Burkart, Kristine Clarke, Andrew C. Mercer, James J. LaClair, Jordan Meier
-
Publication number: 20100297703Abstract: This invention relates to inhibition of microbial lysis via regulation of activity of a lytic enzyme for degrading the cell wall. The lytic enzyme inhibitor and the lysis inhibitor are each composed mainly of the Bacillus subtilis-derived YoeB gene or the YoeB protein encoded by a gene homologous to the YoeB gene. An example of the YoeB protein is a protein consisting of the amino acid sequence as shown in SEQ ID NO: 2.Type: ApplicationFiled: October 16, 2007Publication date: November 25, 2010Inventors: Katsutoshi Ara, Junichi Sekiguchi, Hiroki Yamamoto, Hiroyuki Harada
-
Publication number: 20100291630Abstract: A method for producing a foaming agent is provided, the method comprising cultivating a host cell in a fermentation medium wherein the host cell extra-cellularly secretes a foaming agent and wherein the fermentation medium contains an antifoam which has a cloud point; and then removing the antifoam5 while the temperature of the fermentation medium is above the cloud point.Type: ApplicationFiled: October 16, 2008Publication date: November 18, 2010Inventors: Andrew Richard COX, Andrew Baxter RUSSELL, Christopher Mark TIER
-
Publication number: 20100267846Abstract: An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle comprising a recombinant caveolin protein, an isolated caveolin containing delivery vesicle, a method of making an isolated caveolin containing delivery vesicle and a method of treatment of a disease or condition by delivery of a molecule using the isolated caveolin containing delivery vesicle.Type: ApplicationFiled: September 24, 2008Publication date: October 21, 2010Applicant: THE UNIVERSITY OF QUEENSLANDInventors: Robert Glenn Parton, Piers Jamie Waiser
-
Publication number: 20100267931Abstract: Alternative and improved approaches to the heterologous expression of the proteins of Neisseria meningitidis and Neisseria gonorrhoeae. These approaches typically affect the level of expression, the ease of purification, the cellular localisation, and/or the immunological properties of the expressed protein.Type: ApplicationFiled: June 28, 2010Publication date: October 21, 2010Applicant: NOVARTIS AGInventors: Maria Beatrice ARICO, Maurizio Comanducci, Cesira Galeotti, Vega Masignani, Marizia Monica Guiliani, Mariagrazia Pizza
-
Patent number: 7811793Abstract: A process for preparing a purified refolded monomer or dimer of a bone-derived factor, which comprises subjecting an inclusion body of a bone-derived factor produced by genetic engineering to the following steps a) to c) in sequence: a) introducing a polynucleotide encoding a bone morphogenetic factor into a bacterium, expressing said bone morphogenetic factor in the form of an inclusion body, recovering said inclusion body and treating it with a denaturing agent to obtain a solubilized monomer, b) treating the solubilized monomer without purification directly with a refolding solution to obtain a refolded monomeric bone morphogenetic factor, c) subjecting the refolded monomeric bone morphogenetic factor to purification.Type: GrantFiled: December 15, 2003Date of Patent: October 12, 2010Assignee: Biopharma Gesellschaft zur Biotechnologischen Entwicklung von Pharmaka MBHInventors: Hidetoshi Andou, Jun Honda, Shunjiro Sugimoto, Gertrud Hötten, Rolf Bechtold, Jens Pohl
-
Patent number: 7807808Abstract: The invention relates to bacteria that have increased levels of protein secretion due to genetic modification, to nucleotide sequences and gene structures containing at least one gene coding for a SecA protein having increased levels of protein secretion, to a SecA having increased levels of protein secretion, and to a method for producing desired proteins using the inventive bacteria. The invention also relates to nucleic acids coding for a SecA protein having increased levels of protein secretion, containing a SecA gene sequence or allele, a SecA homologue or derivative, or nucleotide sequences hybridising therewith and comprising at least one mutation. Surprisingly, just one mutation in a nucleotide of a SecA gene leads to increased levels of protein secretion or to protein secretion for the first time.Type: GrantFiled: November 9, 2009Date of Patent: October 5, 2010Assignee: Danisco US Inc.Inventors: Oliver Koberling, Roland Freudl
-
Patent number: 7799552Abstract: Among the inventions disclosed herein are: nucleic acid expression systems for bacteria having an intracytoplasmic membrane system, including, for example, methanotrophic bacteria; recombinant nucleic acid constructs comprising a pmo promoter operably linked to an expressible nucleic acid; cloning vectors suitable for making recombinant nucleic acid constructs and methods for the production of proteins such as membrane proteins.Type: GrantFiled: July 22, 2002Date of Patent: September 21, 2010Assignee: California Institute of TechnologyInventors: Hiep-Hoa T. Nguyen, Sunney I. Chan
-
Patent number: 7794981Abstract: A process is provided for the production of an antibody or a fragment or functionalized fragment thereof using a transformed lower eukaryotic host containing an example DNA sequence encoding the antibody or (functionalized) fragment thereof, wherein the antibody or (functionalized) fragment thereof is derived from a heavy chain immunoglobulin of Camelidae and is devoid of light chains, and wherein the lower eukaryotic host is a mould, preferably belonging to the genera Aspergillus or Trichoderma, or a yeast, preferably belonging to the yeast genera Saccharomyces, Kluyveromyces, Hansenula, or Pichia. The heavy chain fragment can contain at least the whole variable domain. A complementary determining region (CDR) different from the CDR belonging to the natural antibody ex Camelidae can be grafted on the framework of the variable domain of the heavy chain immunoglobulin. The catalytic antibodies can be raised in Camelidae against transition state molecules.Type: GrantFiled: August 11, 2004Date of Patent: September 14, 2010Assignee: BAC IP B.V.Inventors: Raymond Hamers, Cecile Hamers-Casterman, Serge V. M. Muyldermans, Leon G. J. Frenken, Cornelis T Verrips
-
Patent number: 7790416Abstract: The invention relates to a mutant strain of bacteria, which either lacks or contains mutant genes for several key metabolic enzymes, and which produces high amounts of succinic acid under anaerobic conditions.Type: GrantFiled: April 5, 2007Date of Patent: September 7, 2010Assignee: Rice UniversityInventors: Ka-Yiu San, George N. Bennett, Ailen Sanchez
-
Patent number: 7785849Abstract: The present invention relates to novel amino acid and nucleic acid sequences of cyclic nucleotide-specific phosphodiesterases from the parasite Leishmania major. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as methods for producing and using the amino acid and nucleic acid sequences. The invention further relates to the use of these sequences, and of antibodies directed against these sequences, in the diagnosis and treatment of disorders related to the infection of Leishmania major, including the identification of compounds that form complexes with the polypeptides and nucleic acids of the present invention.Type: GrantFiled: September 3, 2004Date of Patent: August 31, 2010Assignees: University of Bern, Otsuka Pharmaceutical Co., Ltd.Inventors: Thomas Seebeck, Andrea Johner, Yasmin Shakur
-
Patent number: 7781574Abstract: Compositions comprising osteogenic factors fused with membrane transduction domains of viral proteins are provided. Also provided are methods of expression and use of such compositions. Further, the methods of making such compositions are also provided. The methods involve transfecting the cells with an isolated nucleic acid comprising a nucleotide sequence encoding a LIM mineralization protein operably linked to a promoter and optionally a membrane transduction domain of a viral protein. Transfection may be accomplished ex vivo or in vivo by direct injection of virus or naked DNA, or by a nonviral vector such as a plasmid. Methods for treating disc disease associated with trauma or disc degeneration are also described.Type: GrantFiled: November 20, 2006Date of Patent: August 24, 2010Inventors: Scott D. Boden, Sreedhara Sangadala
-
Publication number: 20100203592Abstract: The invention provides a process for producing glutathione or ?-glutamylcysteine by culturing in a medium a microorganism with a higher activity of a protein having an activity to transport intracellular glutathione to the outside of cells, and a higher activity of a protein involved in glutathione or ?-glutamylcysteine biosynthesis, compared with that of the parent strain, forming and accumulating glutathione or ?-glutamylcysteine in the medium, and recovering the glutathione or ?-glutamylcysteine from the culture.Type: ApplicationFiled: April 4, 2008Publication date: August 12, 2010Applicant: KYOWA HAKKO BIO CO., LTD.Inventors: Kazuhiko Tabata, Yoshiyuki Yonetani
-
Publication number: 20100196302Abstract: This present invention provides a process for keratin hydrolysis by means of microbiological and/or enzymatic processes. In particular, the keratin is derived from feathers of animals, such as chicken and are submitted to hydrolysis by a strain of Bacillus sp. The hydrolysates have molecular weight lower than 500 Da, which makes them ideal for cosmetic applications, particularly for applications in compositions for treatment of hair fiber re-building.Type: ApplicationFiled: June 30, 2008Publication date: August 5, 2010Inventors: Alane Beatriz Vermelho, Ana Lúcia Vazquez Villa, Ana Maria Mazotto de Almeida, Edilma Paraguai de Souza Dias, Elizabete Pereira dos Santos
-
Patent number: 7767419Abstract: The invention provides a method to efficiently express high levels of a recombinant untagged NT-proBNP for use as a calibrator in NT-proBNP immunoassays.Type: GrantFiled: February 4, 2003Date of Patent: August 3, 2010Assignee: Nexus DX, Inc.Inventors: Azhar Alvi, William Yajima, Roshana Sikora, George Jackowski, Mee-Ra Hong
-
Publication number: 20100183649Abstract: A method for producing picornaviral capsid protein complexes (e.g., picornavirus like particles) in E. coli using a small-ubiquitin-related fusion protein expression system and an E. coli strain used in practicing this method. Also disclosed is use of the picornaviral capsid protein complexes like thus prepared for eliciting immune responses.Type: ApplicationFiled: January 7, 2010Publication date: July 22, 2010Applicant: Academia SinicaInventors: Ting-Fang Wang, Shu-Mei Liang
-
Patent number: 7754223Abstract: The present invention discloses novel proteins, e.g., antigens, from Piscirickettsia salmonis. The present invention further discloses nucleic acids that encode these proteins. The present invention also discloses the use of the proteins, e.g., antigens, and nucleic acids to prepare vaccines against salmonid rickettsial septicemia (SRS). The present invention further provides recombinant Yersinia ruckeri cells to be used to construct vaccines against SRS. The present invention also discloses vaccines that can be used to protect fish from Piscirickettsia salmonis, as well as other pathogens. In addition, the present invention discloses methods of using the vaccines of the present invention to protect fish from SRS as well as from other pathogenic diseases.Type: GrantFiled: October 1, 2004Date of Patent: July 13, 2010Assignee: Eurogentec SAInventors: Michel Thiry, Ingrid Dheur
-
Patent number: 7749731Abstract: The present invention provides improved methods for the production of recombinant peptides from bacterial cells.Type: GrantFiled: June 13, 2007Date of Patent: July 6, 2010Assignee: XOMA Technology Ltd.Inventors: Marc D. Better, Patrick D. Gavit
-
Patent number: 7745175Abstract: This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens (Cp) ?-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing this vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing the Pseudomonas fluorescens system, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cp is also disclosed.Type: GrantFiled: October 26, 2007Date of Patent: June 29, 2010Assignee: Dow AgroSciences LLCInventors: William M. Ainley, Janna Armstrong, Krishna Madduri, Donald J. Merlo, Kelley A. Smith, Mark A. Thompson, Steven R. Webb, Liu Y. Shen
-
Patent number: 7741076Abstract: The expression of the lipidated form of the peptidoglycan-associated protein (PAL) of gram-negative bacteria is achieved through the use of a plasmid containing a tightly regulated promoter. A bacterial host cell is transformed, transduced or transfected with such a plasmid. The host cell is then cultured under conditions such that the lipidated recombinant PAL is expressed. The lipidated recombinant PAL is included in an antigenic composition administered to a mammalian host to immunize against a gram-negative bacterium.Type: GrantFiled: October 20, 2008Date of Patent: June 22, 2010Assignee: Wyeth Holdings CorporationInventor: Benjamin J. Metcalf
-
Patent number: 7736899Abstract: The present invention relates to a method for providing bacterial or yeast cells with the capacity to produce a protein, the amino acid sequence of which comprises at least one unconventional amino acid. The method involves (a) introducing at least one missense mutation in a target codon of a gene encoding a protein required for the growth of the bacterial or yeast cells, where the mutated protein synthesized from the mutated gene is not functional in the bacterial or yeast cells. The method also involves (b) selecting the bacterial or yeast cells obtained in (a) in a culture medium which (1) does not contain a nutrient compensating for the loss of functionality of the mutated protein and (2) contains an unconventional amino acid which restores the functionality of the protein required for growth of the bacterial or yeast cells, in which the unconventional amino acid is that encoded by the target codon.Type: GrantFiled: October 28, 1999Date of Patent: June 15, 2010Assignee: Institut PasteurInventors: Philippe Marliere, Volker Doring, Henning Mootz
-
Patent number: 7723076Abstract: Methods of detecting interactions of a putative ligand with a selectively labeled target molecule, methods of screening for compounds which bind to a selectively labeled target molecule, methods for calculating the dissociation constant of a ligand that binds to a selectively labeled target molecule, and methods to determine the specific amino acids of a target molecule affected by the binding of a ligand, as well as compounds identified by these screening methods, are provided.Type: GrantFiled: August 14, 2006Date of Patent: May 25, 2010Assignee: The Burnham InstituteInventor: Maurizio Pellecchia
-
Patent number: 7723502Abstract: A codon optimized and stabilized luciferase gene based upon the sequence of the natural luciferase gene isolated from Luciola cruciata (Japanese firefly) and a novel recombinant DNA characterized by incorporating this new gene coding for a novel luciferase into a vector DNA for improved activities in mammalian cells, are disclosed. This new luciferase exhibits long-wavelength light emission, as well as improved thermostability and higher expression levels in mammalian cell systems, compared to native luciferase.Type: GrantFiled: October 10, 2008Date of Patent: May 25, 2010Assignee: Marker Gene Technologies, IncInventors: Daniel J. Coleman, John J. Naleway, Gabriele M. Cook
-
Publication number: 20100120710Abstract: The present invention has objects to provide a glucan useful as water-soluble dietary fiber, its preparation and uses. The present invention solves the above objects by providing a branched ?-glucan, which is constructed by glucose molecules and characterized by methylation analysis as follows: (1) Ratio of 2,3,6-trimethyl-1,4,5-triacetyl-glucitol to 2,3,4-trimethyl-1,5,6-triacetyl-glucitol is in the range of 1:0.6 to 1:4; (2) Total content of 2,3,6-trimethyl-1,4,5-triacetyl-glucitol and 2,3,4-trimethyl-1,5,6-triacetyl-glucitol is 60% or higher in the partially methylated glucitol acetates; (3) Content of 2,4,6-trimethyl-1,3,5-triacetyl-glucitol is 0.5% or higher but less than 10% in the partially methylated glucitol acetates; and (4) Content of 2,4-dimethyl-1,3,5,6-tetraacetyl-glucitol is 0.5% or higher in the partially methylated glucitol acetates; a novel ?-glucosyltransferase which forms the branched ?-glucan, processes for producing them, and their uses.Type: ApplicationFiled: April 23, 2008Publication date: May 13, 2010Inventors: Hikaru Watanabe, Takuo Yamamoto, Tomoyuki Nishimoto, Keiji Tsusaki, Kazuyuki Oku, Hiroto Chaen, Shigeharu Fukuda
-
Publication number: 20100112642Abstract: Recombinant forms of DNA sequences for CPD glycosylases, including the bacteriophage T4 gene denV, are described that are capable of expression at high levels. Active CPD glycosylases can be recovered from inclusion bodies resulting from the high expression using, for example, a homogenization process which employs stream mixing, and the active proteins can be used in, for example, topical formulations for treatment of photosensitive diseases. Stream mixing can also be used to solubilize inclusion bodies containing proteins other than CPD glycosylases.Type: ApplicationFiled: January 14, 2010Publication date: May 6, 2010Inventors: Daniel B. Yarosh, Leonard F. Estis, Elyahu Kraus
-
Patent number: 7709260Abstract: The invention relates to a method for preparing closed bacterial ghosts by way of specific interactions between partners of a bioaffinity binding pair, and to the bacterial ghosts which can be obtained in this way. Active compounds can be packed into the closed bacterial ghosts. The closed ghosts can be employed in medicine, in the agricultural sphere and in biotechnology.Type: GrantFiled: August 5, 2004Date of Patent: May 4, 2010Inventor: Werner Lubitz
-
Publication number: 20100086971Abstract: The present invention provides improved media for the cultivation of Clostridium histolyticum and culture supernatants for the biotechnological production of collagenase enzymes. The nutrient media according to the invention comprise one or more peptones from a non-mammalian source, preferably plant-derived peptones. The media can additionally comprise fish gelatin. The invention provides media, culture supernatants comprising Clostridium histolyticum collagenase, and methods to produce said collagenase.Type: ApplicationFiled: June 4, 2009Publication date: April 8, 2010Inventors: Bernhard Suppmann, Werner Hoelke, Artur Hoffmann, Thomas Marx, Kirsten Sonn, Johann-Peter Thalhofer
-
Publication number: 20100086972Abstract: The invention relates to a method for producing biodegradable, functionalised polymer particles, and to the use of the same as medicament carriers.Type: ApplicationFiled: October 8, 2009Publication date: April 8, 2010Applicant: Massey UniversityInventor: Bernd Helmut Adam Rehm
-
Publication number: 20100068728Abstract: The present invention generally provides compositions comprising a polysaccharide derivative, and methods of their preparation and use for the prevention or treatment of diseases caused by Neisseria meningitidis bacteria, particularly group B (NmB) strains, and by E. coli K1. The invention provides a de-N-acetylated PS derivative in which one or more residues of the PS has been modified by de-N-acetylation. The invention also includes derivatives in which one or more of the N-acetyl groups of PS containing de-N-acetylated PS are replaced with other N-acyl groups, usually a lower acyl group of C2-C3. Further, the invention includes de-N-acetylated PS derivatives containing long chain hydrocarbons, as well as conjugates in which the de-N-acetylated PS derivative is linked to a carrier, e.g., a carrier protein.Type: ApplicationFiled: August 12, 2009Publication date: March 18, 2010Inventors: Gregory R. Moe, Dan M. Granoff
-
Publication number: 20100047872Abstract: The present invention provides a process for producing a useful substance by use of a microorganism that lacks in their chromosomal DNA all or part of a gene encoding a protein having the amino acid sequence shown in SEQ ID NO: 1 or a gene encoding a protein having 80% or more, preferably 90% or more, more preferably 95% or more, even more preferably 97% or more, still more preferably 98% or more, and yet more preferably 99% or more homology with the amino acid sequence shown in SEQ ID NO: 1.Type: ApplicationFiled: September 28, 2006Publication date: February 25, 2010Inventors: Makoto Hibi, Hideo Mori
-
Publication number: 20100048689Abstract: The present invention relates to the process for the recovery of conjugated isoflavones of residues and sub-products of food industries based on the use of soy and its derivatives. It also concerns of isoflavones obtained from food composition containing isoflavones and from the fungus genetically modified used in this process, Aspergillus oryzae ATCC 22786 (RIB 430). More specifically, the present invention concerns of a process of conversion of conjugated isoflavones, in the form of isoflavone malonate and acetates, in glucosylated isoflavones, which through fermentative and enzymatic processes are transformed into aglycone isoflavones. The products obtained in this process, pass to show a promising therapeutic as nutritive application as previously described, and may be used as a functional food or as a functional ingredient.Type: ApplicationFiled: December 14, 2006Publication date: February 25, 2010Inventors: Kun Park Yong, Claudio Lima De Aguar, Maria Cristina Youn Lui
-
Publication number: 20100047873Abstract: The present invention relates to an improved process for the production of Daptomycin by fermentation with Streptomyces roseosporus, in the presence of n-decanal or Cuphea oil as sources of the n-decanoyl side chain. These reagents allow to reduce toxicity effects on the bacteria and to avoid the use of solvents in the feeding solution.Type: ApplicationFiled: July 30, 2009Publication date: February 25, 2010Applicant: ANTIBIOTICOS S.p.AInventors: Gianluca BERTETTI, Antonella Malcangi, Roberto Muraca, Guido Trione, Alessia Rossi
-
Patent number: 7666621Abstract: A novel surface exposed protein of Haemophilus influenzae or related Haemophilus species is described. The protein named protein D is an Ig receptor for human IgD and has an apparent molecular weight of 42,000. Protein D can be detected in all of 116 encapsulated and non-encapsulated isolates of H. influenzae studied. The protein from all strains shows in addition to the same apparent molecular weight immunogenic similarities since protein D from all strains interacts with three different mouse monoclonal antibodies and monoclonal human IgD. A method for purification of protein D is described. Cloning of the protein D gene from H. influenzae in E. coli is described as well as the nucleotide sequence and the deduced amino acid sequence.Type: GrantFiled: September 15, 2006Date of Patent: February 23, 2010Inventor: Arne Forsgren
-
Publication number: 20100028952Abstract: The present invention provides methods for production and purification of active chromoproteins produced by Actinomadura sp. 21G792. The chromoproteins are useful for developing pharmaceutical compositions and treating diseases such as cancer or bacterial infections.Type: ApplicationFiled: June 21, 2007Publication date: February 4, 2010Applicant: WYETHInventors: Eugene Joseph Vidunas, Gow-Jen Tsai, Ping Cai, Justin Moran, Pamela Sue Fink, Lourdes Jeanette Gordon